Matches 251 - 300 out of 329 < 1 2 3 4 5 6 7 >
Match Document Document Title
5861164 Vaccination against diseases resulting from pathogenic responses by specific T cell populations  
The present invention provides vaccines and a means vaccinating a host so as to prevent or control specific T cell medicated proliferative diseases. The vaccine is composed of a pharmaceutically...
5861158 Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor  
This invention provides a method of improving a transplantation of hematopoietic cells from a donor to a recipient to treat a hematopoietic cell tumor in the recipient comprising immunizing the...
5861381 Pharmaceutical composition for the treatment of a malignant tumor  
A pharmaceutical composition which comprises a recombinant vaccinia virus containing a DNA fragment encoding for a polypeptide recognized by a particular antibody H23, which recognizes a particular...
5858363 Target specific antibody-superantigen conjugates and their preparation  
A soluble antibody conjugate comprising an antibody linked to a structure which is recognizable by T-cells and has the ability to direct T-cells to lyse the target cell, which is recognized by the...
5843448 Tumor rejection antigen precursor  
The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use....
5840317 Composition comprising tumor cell lines containing GD2 ganglioside GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen  
A new polyvalent melanoma cell vaccine is disclosed comprised of one or more allogeneic melanoma cell lines which contain effective concentrations of melanoma associated antigens. Further disclosed...
5837824 Epitope which binds to monoclonal antibody  
The invention relates to the epitope which binds monoclonal antibody BW 835, DSM ACC 2022, and the use of the epitope for diagnosis and therapy.
5837231 GM-CSF administration for the treatment and prevention of recurrence of brain tumors  
A method for inhibiting the growth of brain tumors comprising peripheral administration of GM-CSF in combination with brain tumor antigen.
5830464 Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy  
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
5820872 Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor  
Methods and pharmaceutical compositions for improving the effectiveness of radiation therapy for treating a subject having an internal solid tumor malignancy are disclosed. The methods include...
5820880 Liposomal formulation  
Depending on the antigen encapsulated, liposomal formulations are subject to instability in the presence of alum. Formulations containing a nonionic detergent as a stabilizing agent avoid this...
5807559 Compositions for generating T cell immunity against carbohydrate structures  
The present invention relates to a novel class of immunologically active compounds, to processes for their production and to their use in therapy. In particular, the invention provides immunogenic...
5808005 Human carcinoma antigen  
A glycoprotein antigen which is generally characteristic of human carcinomas, regardless of the tissue associated with the carcinoma--human carcinoma antigen (HCA)--and which is generally not...
5788985 Vaccine composition for eliciting an immune response against N-glycolylated gangliosides and its use for cancer treatment  
The invention provides novel uses for n-glycolylated gangliosides, or derivatives and/or oligosaccharides thereof. The invention further provides methods of obtaining such gangliosides, as well as...
5788963 Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy  
Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic prostate cancer are disclosed. In one embodiment, human...
5770201 HA-2 antigenic peptide  
The present invention discloses the first peptide sequence of a so called minor H antigen, The minor H antigens are associated with the Graft-versus-Host Disease. The peptide and its derivatives...
5766588 Tumor immunotherapy using anti-idiotypic antibodies  
The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which...
5760178 Human and rat variants of glycoprotein CD44 containing an additional extracellular domain associated with metastatic potential  
A monoclonal antibody (MAb1.1ASML) directed against a surface glycoprotein of the metastasizing rat pancreatic carcinoma cell line BSp73ASML, was used to identify and isolate a complementary DNA...
5759792 Antigenic regions of tumour-liberated particles (TLP) complexes and antibodies against the same  
Peptides comprised within the 100 KDa protein of the TLP complex (i.e., released proteins from tumors) having antigenic activity as well as antibodies thereof, able to react with TLP for diagnostic...
5747048 Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates  
A method of producing monoclonal antibodies that bind to human cancer-associated mucin-type glycoprotein antigens comprising: (1) immunizing a host with a core structure of a mucin-type...
5736318 Method and kit for evaluating human papillomavirus transformed cells  
The invention provides methods and kits for determining the extent of interaction and/or inactivation between a cyclin/cyclin-dependent kinase inhibitor and the human papilomavirus E7 oncoprotein...
5700649 Method of detection of urinary tumor associated antigen  
The present invention describes Urinary Tumor Associated Antigen (UTAA), its isolation and use in diagnostic assays. In particular, UTAA has been identified in samples from cancer patients, in some...
5686068 Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof  
New peptides derived from the MAGE-2 molecule and which bind to HLA-A*0201 molecules are disclosed. Some of these are especially useful because, when complexed to their HLA-A*0201 partner...
5683886 Tumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereof  
A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor...
5681562 Lymphokine gene therapy of cancer  
A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to...
5674486 Cancer immunotherapy with carrier cells  
A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to...
5662907 Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes  
The present invention relates to compositions and methods for treating cancer. The invention provides peptides based on a 9 residue epitope derived from the product of the tumor-associated gene...
5654408 Melanoma-associated antigens identified by monoclonal antibodies  
A new cell line has been made which is capable of producing an antibody that reacts with melanoma associated tumors cells. Antigens capable of reacting with the new antibody have been isolated and...
5648226 Isolated peptides derived from tumor rejection antigens, and their use  
A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as GAGE tumor...
5614371 Ri fusion antigen recognized by antibodies associated with paraneoplastic opsoclonus and methods of use thereof  
An isolated nucleic acid sequence encoding Ri paraneoplastic antigenic polypeptide is provided by this invention. This invention also provides a purified Ri antigenic polypeptide and compositions...
5595738 CTAA 81AV78, the antigen recognized by human monoclonal antibody 81AV78  
A lipid antigen found in colon, breast, lung, ovarian and pancreatic human adenocarcinomas identified by reactivity with human monoclonal antibody 81AV78, and the use of the antigen in vaccines.
5591430 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof  
Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the...
5582831 Anti-tumor vaccines  
An immunogen derived from modified tumor cells and capable of inducing an anti-tumor immune response is prepared in accordance with the invention by exposing tumor cells to a crosslinking agent,...
5558995 Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof  
The invention relates to the identification of complexes of HLA-C-clone 10 and MAGE-1 derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this...
5550214 Isolated antigenic oncogene peptide fragments and uses  
An isolated antigenic peptide fragment that is an isolated oncogene protein fragment is disclosed. The isolated peptide fragment of the invention is a peptide either 9 or 10 amino acid residues in...
5545717 Plasmilar and plasmilar antibody compositions as malignant cell markers  
Disclosed are substantially pure plasmilar polypeptide and antibodies which bind plasmilar.
5506119 DNA encoding variant CD44 surface proteins associated with metastatic tumors  
The presence of certain extracellular regions ("ECR") from human and rat variants of the CD44 membrane glycoprotein have been found to be associated with metastasis ability in tumor cells. Isolated...
5500215 Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones  
The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the...
5484596 Active specific immunotherapy  
This invention relates to a method of cancer therapy for treating human patients with resectable solid tumors to inhibit recurrence and formation of metastases, comprising surgically removing tumor...
5478556 Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor  
A breast cancer vaccine which comprises a mixture of tumor associated antigens (TAA) with low doses of recombinant interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF).
5290551 Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten  
The invention is a haptenized tumor vaccine for the treatment of cancer. Treatment of cancer patients with an autologous, vaccine preceded by low dose cyclophosphamide (CY) induces delayed-type...
5273745 Virus-modified tumor vaccines for immunotherapy of tumor metastases  
The invention discloses a virus-modified tumour-specific vaccine consisting of corresponding separated tumour cells inactivated by irradiation and incubated with NDV (Newcastle Disease Virus) under...
5194384 Method for preparing human meloma vaccine  
There is disclosed a method of preparing a vaccine suitable for administration to humans for the prevention or treatment of cancer. The vaccine is prepared by culturing human cancer cells in a...
5173292 Monoclonal antibodies which specifically recognize galactosyl-globoside, compositions containing same and methods of using same  
This invention provides a composition useful for diagnosing cancer which specifically recognizes a galactosyl-globoside. Preferably, the composition is a monoclonal antibody which specifically...
5156841 Anti-tumor vaccine  
An antitumor vaccine utilizing oncoproteins as immunogen is disclosed. The oncoprotein could be administered either as isolated, substantially pure product or expressed through a recombinant...
5141742 Vaccines against melanoma  
Peptides or proteins related to a melanoma associated antigen are described. These are produced in large quantities via recombinant DNA techniques and/or by chemical synthetic methods. The peptides...
5102663 Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3  
The present invention provides a vaccine for stimulating or enhancing in a subject to whom the vaccine is administered, production of antibodies directed against 9-O-acetyl GD3 ganglioside...
5100662 Steroidal liposomes exhibiting enhanced stability  
The present invention relates to novel liposomes and liposome-like structures (vesicles) comprising an amount of a derivatized sterol either alone or in combination with additional liposome-forming...
5049373 Method for selection of primate tumor-associated antigens suitable as in vivo targets for antibodies  
The present invention is a process for the selection of antigens which are suitable targets for in vivo antibody localization in human tumors or other altered (or diseased) tissue. The process...
5045320 Large multivalent immunogen  
Immunization and/or therapeutic in vivo introduction of ligands bound alone or in combination with other molecules, arrayed on solid supports having greater then about 0.2μ diameter to elicit and...
Matches 251 - 300 out of 329 < 1 2 3 4 5 6 7 >